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Abstract 
Community-acquired  methicillin-resistant
Staphylococcus  aureus has  become  a  well-
established pathogen with alarming rates dur-
ing the last decade. The current situation of
this bacteria in pediatric infections is very lim-
ited and motivated us to conduct this study.
This  is  a  retrospective  and  analytical  study
including patients less than 18 years of age
with the diagnosis of skin or soft tissue infec-
tions in 2008 and 2009 meeting the criteria of
Community-acquired  infection.  A  prevalence
of 41.9% among skin and soft tissue infections
was found. Inducible resistance to clindamycin
was detected in 1.3% of the strains and the
infection  shows  a  seasonal  predilection  for
summer  (P=0.003);  57.8%  of  the  cases
required hospitalization with a mean stay of
3.3±2.5 days. The susceptibility to clindamycin
and co-trimoxazole is 88 and 97% respectively.
The  resistance  to  erythromycin  has  reached
92%. The main diagnoses at presentation was
gluteal abscess plus cellulitis (34.2%).
The prevalence of CA-MRSA is trending up
and seems to become a large burden for the
health system in our community. Clindamycin
is still an excellent option in the community
setting since inducible clindamycin resistance
is extremely low in this community. Co-trimox-
azole  should  be  kept  as  a  reserved  drug  to
avoid the rapid resurgence resistance in the
community. 
Introduction 
Community-acquired  methicillin-resistant
Staphylococcus aureus(CA-MRSA) has become
a  well-established  pathogen  in  the  United
States and the rest of the world. Even though a
broad variety of infections are associated with
this pathogen, infections localized in the skin
and soft tissues are predominant among the
general population. 
The  prevalence  of  CA-MRSA  infections  in
the  children  population  has  progressively
increased over the last decade, and a recently
published study reported an increase from 6 to
42% in a 10 years surveillance study in the
United States during the last decade.¹
Similar situation is described in different
latitudes of the world where the incidence and
prevalence of CA-MRSA has reached alarming
rates varying from 28 to 85% between during
the last decade.2-6
Resistance  of  CA-MRSA  to  other  types  of
antibiotics has developed over recent years as
well. Ever since a laboratory at Johns Hopkins
Hospital  reported  induction  of  clindamycin
resistance  in  vitro  in  erythromycin-resistant
MRSA, clinicians have been wary about using
clindamycin  to  treat  CA-MRSA  infections.
Fortunately, the diffusion test (D-test) can be
used to reliably detect erythromycin-resistant
MRSA  strains  with  inducible  clindamycin
resistance.7 The  prevalence  of  inducible
macrolide-lincosamide-streptogramin B resist-
ance (MLSBi) among S. aureus isolates in the
community setting has also increased over the
years and is currently placed between 2-14% in
the United States.8,9 Consequently, ineffective
antibiotic treatments and longer hospital stays
create a great burden to healthcare system.  
In one of the few published studies in New
York City twelve years ago, CA-MRSA account-
ed for only 10% of infections requiring hospi-
talization.10 The current situation of pediatric
CA-MRSA infections in New York and Brooklyn
is very limited in literature and thus motivated
us to conduct this study among our children
population. 
Materials and Methods
This was a retrospective and analytical study
conducted at Woodhull Medical Center, a com-
munity  hospital  currently  affiliated  with  the
New  York  University  (NYU)  and  located  in
North  Brooklyn,  serving  a  population  of
416,559  people.  Institutional  Review  Board
approval from NYU and Health and Hospitals
Corporation  (HHC)  was  obtained  before  the
review of medical records. No informed con-
sent was needed.
All patients less than 18 years of age with
the diagnosis of skin or soft tissue infection
between  January  2008  and  December  2009
were  included  initially  in  the  review.
Community-acquired  (CA)  infection  was
defined  as  one  presenting  in  those  patients
without a history of hospitalization, surgery, or
dialysis for at least one year prior to presenta-
tion; without a indwelling catheter or percuta-
neous medical device at the time of culture;
and with infections beginning within the first
48  hours  of  hospitalization.  Only  those
patients meeting the CDC criteria of commu-
nity-acquired infection and positive culture of
MRSA were included in the final analysis. 
All cultures obtained were processed in the
Microbiology  Department  at  Kings  County
Hospital, Brooklyn, New York according to the
National  Committee  for  Clinical  Laboratory
Standards. Antimicrobial susceptibilities were
determined  for  the  following  antimicrobials:
clindamycin, erythromycin, moxifloxacin, gen-
tamycin, tetracycline, rifampin and co-trimox-
azole. D-Test in each strain resistant to eryth-
romycin and sensitive to clindamycin was per-
formed  in  order  to  detect  the  presence  of
MLSBi.
The data collected were analyzed using the
JMP  6.0  statistical  discovery  program  (SAS
Institute Inc., Cary, NC, USA), and the Pearson
chi-square test was used to test significance in
the monthly distribution of cases.
Results  
In the initial review, there were a total of
603 cases, 189 of which incision and drainage
with further culture was obtained. Among the
189  cases,  126  tested  positive  for
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Staphylococcus aureus, and 76 of the 126 were
resistant to methicillin. 
Among  the  76  MRSA-positive  cases,  57%
were female, 43% were male; 53.9% and 46.1%
presented  in  2009  and  2008,  respectively.
When  comparing  the  proportion  of  cases
between months, the summer months of the
year (June 13.1%, July 18.4%, August 15.7%)
were significantly higher than other months
(P  =  0.003)  (Figure  1).  57.8%  of  the  cases
required hospitalization with a mean stay of
3.3±2.5 days. The majority of main diagnoses
at  presentation  were  lower  extremity  infec-
tions, of which gluteal abscess plus cellulitis
was  most  common  (34.2%),  followed  by  leg
abscess (11.8%) and knee region abscess plus
cellulitis (6.5%). Infections in the abdomen,
trunk, face, and upper extremities accounted
for the remaining proportion of cases. 
The  susceptibility  pattern  is  visualized  in
Figure 2. D-Test was performed for all patients
with strains resistant to erythromycin and was
positive only in one case (1.3%). Clindamycin
(65.1%),  followed  by  cephazolin  (8.4%)  and
vancomycin (5.2%) were the preferred drugs
in  the  initial  treatment  for  hospitalized
patients.  Similarly,  clindamycin  (54.9%),  fol-
lowed by cephalexin (19.6%) and co-trimoxa-
zole (9.8%) were the favorite drugs chosen as
initial therapy in outpatients.
Discussion 
In  one  of  the  largest  surveillance  studies
across the United States, Mera et al. recently
found a five-fold increase, from 6.3 to 36.3%, in
the proportion of CA-MRSA isolates from chil-
dren younger than fifteen between 1998 and
2007.1
Our  study  found  a  prevalence  of  41.9%
among cultured skin and soft tissue infections,
which is alarming considering that culture was
obtained only in 31% of the cases. Despite the
high prevalence of their use, clindamycin and
co-trimoxazole  are  acceptable  as  first-line
antibiotics to treat skin and soft tissue infec-
tions in our community given CA-MRSA’s sus-
ceptibility. Moxifloxacin and other less com-
monly  used  antibiotics  in  children  such  as
rifampin,  gentamycin,  and  tetracyclines  pos-
sess a very low rate of resistance in our strains
and should be reserved for only special situa-
tions in pediatrics. The resistance to erythro-
mycin is alarming. Kaplan et al conducted a
three-year  surveillance  study  in  Houston
showing extremely high rates of resistance to
erythromycin  comparable  with  the  92.2%
found in our study.11 Along the same lines, the
rates of resistance to clindamycin in our study
have  doubled  in  six  years  in  Houston  and
Baltimore  from  6-12%.11,12 However,  despite
the increased use of this antibiotic and the
slight increase in its resistance, clindamycin
can still be considered acceptable for clinical
use.  Inducible  resistance  to  clindamycin  is
very low in our community (1.3%), compared
to those reported in literature in the United
States (2.4-16%) and the rest of the world (2-
94%).8,11,12
Genetically  distinct  strains  of  Staphylo  -
coccus aureus circulates around the world and
across the United States, conferring a variety
of  virulence  and  resistance  factors.  The
abscense of MLSBi genotype is specially recog-
nized  among  ST8:USA300  strains,  the  most
prevalent  MRSA  associated  with  community
type infections and may explain this variabili-
ty in the expression of inducible resistance.2,13
One study conducted in Brooklyn determined
that ST8:USA300 was the most prevalent strain
in the area.14
The  presence  of  MLSBi  and  its  clinical
implication should be individualized in each
case. Treatment failure was more frequently
reported in severe systemic MRSA infections,
but  clindamycin  may  still  play  an  important
role in mild to moderate skin and soft tissue
infections with similar rates of success than in
the absence of MLSBi.15
Kaplan and Szczesiul found a higher inci-
dence  of  cases  during  warm  months  of  the
year.11,12 We found a similar seasonal variance
in our study. In vitro studies have demonstrat-
ed that the optimum temperature for growth
and productions of toxins for Staphylococcus
aureus is around 35 to 37°C. This can explain
the tendency for peak incidence of cases in hot
temperatures.  
Frequent  monitoring  of  the  prevalence  of
antibiotic-resistances  in  MRSA  infections  is
important in identifying resistance trends and
guiding treatment since the presence of this
frightful bacteria alone leads to unnecessary
use of systemic antibiotics and costly hospital-
izations,  without  even  first  trying  with  oral
antibiotics and drainage, treatments known to
be successful in the literature.    
Conclusions
In conclusion, the prevalence of CA-MRSA is
trending up over time and seems to become a
large burden for the health system in our com-
munity  as  in  the  rest  of  the  United  States.
Clindamycin is still an excellent option as first-
line treatment in the community setting since
inducible clindamycin resistance is extremely
low in this community despite high resistance
to  erythromycin.  Co-trimoxazole  should  be
kept as a reserved drug for those cases not
responding  to  other  antibiotics  to  avoid  the
rapid resurgence of co-trimoxazole resistance
in the community. 
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